The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 29, 2013
Filed:
Nov. 30, 2009
Thomas Joseph Caulfield, Lebanon, NJ (US);
Jennifer Williford Clemens, Somerset, NJ (US);
Robert S. Francis, Easton, PA (US);
Brian Scott Freed, Phillipsburg, NJ (US);
Stanly John, Basking Ridge, NJ (US);
Tieu-binh Le, Bridgewater, NJ (US);
Brian Pedgrift, Flemington, NJ (US);
Antonio Daniel Ramos, Flemington, NJ (US);
Gerard Charles Rosse, Exton, PA (US);
Martin Smrcina, Tucson, AZ (US);
David Squire Thorpe, Tucson, AZ (US);
William Shelly Wire, Tucson, AZ (US);
Jianhong Zhao, Annadale, NJ (US);
Thomas Joseph Caulfield, Lebanon, NJ (US);
Jennifer Williford Clemens, Somerset, NJ (US);
Robert S. Francis, Easton, PA (US);
Brian Scott Freed, Phillipsburg, NJ (US);
Stanly John, Basking Ridge, NJ (US);
Tieu-Binh Le, Bridgewater, NJ (US);
Brian Pedgrift, Flemington, NJ (US);
Antonio Daniel Ramos, Flemington, NJ (US);
Gerard Charles Rosse, Exton, PA (US);
Martin Smrcina, Tucson, AZ (US);
David Squire Thorpe, Tucson, AZ (US);
William Shelly Wire, Tucson, AZ (US);
Jianhong Zhao, Annadale, NJ (US);
Sanofi, Paris, FR;
Abstract
The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.